Kaposi's sarcoma-associated herpesvirus (KSHV) vOX2 is a cell surface glycoprotein expressed during viral lytic replication to suppress host inflammatory reactions. Here we have characterised vOX2 with biochemical, biophysical and bioinformatics tools and as a result propose a 3-dimensional model for vOX2 based on structural and functional homology with the PD-L1 protein. To validate this model, vOX2 was characterised by analytical ultracentrifugation (AUC) and circular dichroism spectroscopy (CD). The results identified the potential glycosylation sites and revealed that vOX2 is predominantly a beta-folded molecule with an RGD adhesion motif exposed on the C-terminal domain. The protein exists in monomer-dimer equilibrium similar to its IgV-type folded homologues, with 30-36% glycosylation and the molecular weight of the extracellular fragment of molecule is 32.0-33.6 kDa, much less than 50 kDa. Thus, the structural similarity to PD-L1 verifies its immunomodulatory potential and the RGD motif suggests an adhesive capacity.
Introduction
KSHV which belongs to the Herpesviridae, is the aetiological agent of Kaposi's sarcoma (Chang et al., 1994) and primary effusion lymphoma (Cesarman et al., 1995; Bouvard et al., 2009) . It may also cause multi-Centric Castle man's disease (Soulier et al., 1995) . Up to one-third of the genome specifies proteins with either potential or demonstrated immune modulation (Rezaee et al., 2006; Aresté and Blackbourn, 2009) . Open reading frame (ORF) K14, encodes the vOX2 protein which shares 40% sequence identity with the mammalian OX2 (now is called CD200) (FosterCuevas et al., 2004) . Signal delivery of OX2 occurs through binding to CD200R . The distribution of CD200R family members in humans is more restricted than that of CD200, with the receptor being expressed on myeloid and T cells (Wright et al., 2003) . Sequentially, these data suggest that the CD200-CD200R interaction locally modulate inflammatory cell activities at the sites of inflammation. In support of these findings, CD200 has been identified as an immuno-regulatory molecule in immune privileged organs such as CNS which may confer additional protection against immune destruction through regulation of macrophage activity. In rodents, antibody-mediated blockade of CD200R resulted in macrophage activation which was followed by CNS damage and also aggravated experimental autoimmune encephalomyelitis (EAE) (Meuth et al., 2008) . Activated macrophages in CD200-deficient mice, led to rapid onset of EAE . In contrast, elevated neuronal expression of CD200 was followed by reducing EAE pathogenesis (Chitnis et al., 2007) . In humans, CD200 expression in MS lesions and lesion centres was downregulated which could result in an interrupted balance in macrophage activation (Koning et al., 2007; Koning et al., 2009 ). Furthermore, in SLE patients, CD200R expression was decreased in CD4 þ lymphocytes and DCs; blocking of CD200R by CD200:Fc resulted in increased CD4 þ T-cell proliferation and decreased DCs migration and Th17 cells differentiation (Li et al., 2012) . Also CD200R expression was shown on mouse and human mast cells, in these cells, CD200R engagement inhibited mast cell degranulation and decreased IL-13 and TNF secretions (Cherwinski et al., 2005) . From the other point of view, CD200-CD200R signalling could benefit tumor cells and CD200 gene knockout mice were resistance to tumor induction; lymph nodes of these mice contained more regulatory T cells which tend to home tumours (Rygiel et al., 2012) . Moreover, CD200 over-expression in transgenic mice could facilitate tumor cell metastasis while neutralising CD200 could result in decreased metastasis and increased antitumor cytotoxic lymphocytes (Gorczynski et al., 2011) . Since vOX2 like CD200 is a ligand of CD200R (Foster-Cuevas et al., 2004) , the viral protein signalling pathways seem to be like their cellular counterpart which may inhibit the main components of immune responses. Previously we constructed engineered form of vOX2 in which the extracellular domain of the viral protein was fused with the C-terminal domain of human IgG 1 Fc (Rezaee et al., 2005) . Functional studies with a soluble, recombinant form of vOX2 (vOX2:Fc) revealed that it selectively reduced the oxidative burst of primary human neutrophils and the production of IL-8 by rIFN-γ-treated cells of a myeloid lineage cell line to basal levels (Rezaee et al., 2005) . Transfected NK cells and basophil functions were also down-regulated by vOX2 (Shiratori et al., 2005) . However, vOX2 effects on macrophages have been reported to be both proinflammatory and anti-inflammatory depending on microenvironment in contradictory studies (Chung et al., 2002; FosterCuevas et al., 2004; Salata et al., 2009) . Importantly, by providing negative costimulatory signal to cytotoxic T cells by vOX2 transfected antigen presenting cells, vOX2 might lead to survival of KSHV-infected cell; in parallel, CD200 provided a similarly negative regulatory signal to CTL ; MHC class I and class II down-regulation induced by vOX2 (Salata et al., 2009 ) may also result in decreased cellular responses, a condition that will benefit infected cells.
In the present study, PD-L1 was selected as a template to predict the vOX2 three-dimensional (3D) structure, in order that in future the functional determinants of vOX2 can be understood. PD-L1, a type 1 transmembrane protein, is a member of the B7 family and also belongs to the Ig-superfamily (Collins et al., 2005) . It is expressed on DCs (Bryant-Hudson and Carr, 2012), T cells (Channappanavar et al., 2012) and macrophages (Rodriguez-Garcia et al., 2011) . Engagement of PD-L1 to its receptor, PD-1, which is expressed on T and B lymphocytes (Agata et al., 1996) , negatively regulates T lymphocytes (Freeman et al., 2000; Carter et al., 2002; Liechtenstein et al., 2012) . PD-1 pathway could affect broad ranges of immune responses and exerts significant effects in clinical conditions such as autoimmunity, viral infection and anti-tumor immunity . Like PD-L1, vOX2 has negative regulatory activity for CD8 þ T cell and neutrophil function (Rezaee et al., 2005) . In these studies, vOX2:Fc was expressed from CHO cells as an Fc fusion protein (Rezaee et al., 2005) . We provide the first structural analysis of vOX2 in that regard by reconstructing the predicted three-dimensional structure of the viral protein on the basis of biophysical and bioinformatics data.
Results

vOX2 structural model based on its homology with PD-L1
Inspection with PSI-BLAST showed that vOX2 protein has one IgV like domain between residue 33 and residue 127 (Fig. 1A) . This Ig-like domain contains two cysteine residues at positions 39 and 109 (Fig. 2B) , which are predicted to form a disulphide bond. These data revealed that KSHV vOX2 belongs to the Ig superfamily molecules.
PD-L1 is a negative regulatory ligand of PD-1 Liechtenstein et al., 2012) that also belongs to the Igsuperfamily (Collins et al., 2005) . Like PD-L1, vOX2 has negative regulatory activity for CD8 þ T cell (Karen Misstear et al., 2012) and neutrophil function (Rezaee et al., 2005) . Since vOX2 has structural and functional similarities with PD-L1, this molecule (PDB entry: 3FN3) was chosen as the template for modelling of KSHV vOX2. Regarding these similarities, over 1000 structural models were generated by MODELLER and 10 structures with the lowest molpdf score were selected, and their energy minimised by HyperChem. The most valid model achieved 96.3 ERRAT score (Fig. 1B) . In the present study among 10 energy minimised structures for vOX2, the best model with high resolution is shown in Fig. 1C (Fig. 3A , lane 3 and lane 4). The predicted (PeptideMass, ExPASy) size of the vOX2 fragment is 24.6 kDa. However, when constructed vOX2:Fc was cleaved with Factor Xa, the molecular size of vOX2 in the SDS PAGE gel was 50 kDa (Fig. 3A, lane 1) .
The difference between predicted and observed molecular sizes suggested the possibility of post-translational modification of vOX2, which was more likely to be glycosylation. Using glycosylation server, six consensus N-glycosylation sites were identified within the vOX2:Fc amino acid sequence including (NetNGlyc, CBS Prediction Server). Of these residues, five are contained within vOX2, and one (Asn 321 ) is contained within the Fc fragment (Fig. 4A ).
In order to determine whether the increased molecular mass of extracellular domains of vOX2 on SDS PAGE gel was because of glycosylation, the purified vOX2 fragment of the Fc fusion protein was treated with PNGase F, and the deglycosylated bands were identified by protein mass fingerprinting technique (James et al., 1993; Yates et al., 1993) . As a result of deglycosylation, the diffuse band of vOX2 originally migrated at 50 kDa (Fig. 4B , lane 1) shifted to 25 kDa (Fig. 4B, lanes 2-4) , consistent with the predicted molecular mass of amino acid sequences in bioinformatics analysis. Thus, the results suggest that vOX2 is a highly glycosylated protein.
To evaluate vOX2 post translation glycosylation, an analytical ultracentrifugation method was used, since molecular weight of glycosylated proteins is regularly overestimated by SDS PAGE (Hames 1982) . For this purpose the uncleaved vOX2:Fc construct was analysed due to its homogeneity in solution ( Fig. 5A) with the values of sedimentation coefficient 6.12 S and molecular weight of 134 kDa. The latter is close to the actual mass expected for Fc dimer (52.8 kDa) plus dimeric vOX2 (49.2 kDa) together with the associated carbohydrates attached: two Fc-originated carbohydrate chains (3.5 kDa each) and a maximum of 12 carbohydrate chains of unknown molecular weight on the vOX2 dimer (amounting to 20 kDa of carbohydrates for dimeric vOX2 if the carbohydrate chains of vOX2 was assumed to be similar to those on Fc).
The molecular mass of vOX2:Fc in solution was verified using sedimentation equilibrium (SE) analysis. SE data were fitted globally with a single species model ( Fig. 5B and C) . The resultant molecular mass of 1327 10 kDa agrees well with the mass calculated from its amino acid sequence and that estimated for the glycosylation. The buoyant mass resulted from SE experiment was converted to a molecular mass using a possible range of partial specific volumes (v) of 0.59-0.63 ml/g (at 4 1C) for carbohydrates (Schuster et al., 1994) . Since the glycosylation of vOX2 is unknown, we have determined the buoyant molecular weight of vOX2:Fc, and as a next step, estimated the contribution of carbohydrates to the mass of vOX2:Fc, using Eq. (2) as 28% of the total mass. In order to determine the molecular weight of carbohydrates bound to vOX2 we used this parameter to "deconvolute" vOX2:Fc (employing the known values for the protein component of vOX2 and Fc and knowledge of the carbohydrate content for the Fc part (Deisenhofer, 1981) . The mass of carbohydrates per vOX2 monomer was calculated to be between 7.5 kDa and 9 kDa, for plausible carbohydrate v(v of vOX2 will be 0.695 ml/mg). Therefore, the extracellular domains of glycosylated vOX2 monomer should have a molecular mass in the range of 32.0-33.6 kDa, corresponding to 30-36% glycosylation.
vOX2 mostly is a beta-stranded protein
The secondary structure of vOX2 was determined experimentally by CD which refers to the differential absorption of left and right circularly polarised light. The far UV CD spectrum of vOX2 showed a strong negative peak between 230 nm and 210 nm with a minimum at around 218 nm ( Fig. 6A ) and small positive peak at 196 nm. This configuration of far UV CD spectrum is typical for that of a protein with a predominantly β -fold structure (peak 190 and 220 indicate α-helix and β-sheets, respectively). Indeed, the CONTIN procedure (Provencher and Glockner, 1981) provides secondary structure estimations of 3% α-helix, 38% β-sheet, 24% β-turn and 35% remainder for such a UV spectrum. These data are consistent with the modelling data that showed that secondary structure of vOX2 was mainly ($62%) composed of β-strands ( Fig. 1C-3 ). The near UV CD spectrum displays a broad peak between 270 and 330 nm (Fig. 6B ). These data are consistent with the frequency of aromatic amino acids in the protein, which are present at the following frequencies: phenylalanine (2.2%), tyrosine (1.4%) and tryptophan (3.5%) (data are not shown). Tryptophan residues in folded proteins generally give peaks close to 290 nm; tyrosine and phenylalanine residues give rise to peaks between 275 and 282 nm and 255 and 270 nm, respectively. This pattern of the near UV CD spectrum for vOX2 suggests that these aromatic residues are located in asymmetric environments and are characteristic of the tertiary structure of a folded protein.
vOX2 dimerises in solution
Cleaved vOX2 was examined for the presence of oligomeric species in solution via SV size-distribution analysis. The distribution c(s) (Fig. 5A ) demonstrates two easily distinguishable peaks which could be interpreted as both monomeric and dimeric forms of vOX2 present in solution. The integrated values of sedimentation coefficient appeared to be lower than calculated s for spherically shaped particles of correspondent molecular weight: s 20,w 0 for monomeric and dimeric vOX2 was measured as 2.82 S and 4.6 S respectively, while s (sphere) were estimated as 3.5 S and 5.2 S for monomer and dimer, respectively. This fact implies to some elongation of vOX2 from spherical shape and, the presence of carbohydrate chains is also a reason for decrease in the value of sedimentation coefficient. All examined concentrations of vOX2 were fitted with the value of friction ratio about 2, which reflects the heavy glycosylation of vOX2 molecule. The large difference between sedimentation coefficients of monomer and dimer suggests "side-to-side" dimerisation.
We applied hydrodynamic bead modelling to the homology model to validate it against actual experimental results. Thus, the value of sedimentation coefficient for vOX2 glycosylated monomer calculated by programme HYDROPRO (Garcia De La Torre et al., 2000) from atomic coordinates of the homology model was 2.83 S and in excellent agreement with experimental sedimentation velocity data.
The strength of dimerisation for cleaved vOX2 was determined with sedimentation equilibrium. The weight-average mass of the solute was 5573 kDa with v of 0.695 ml/mg as it was determined above. This value of mass is an intermediate value between molecular weight of monomeric and dimeric vOX2 (approximately 32 and 64 kDa respectively, as estimated above by de-convolution of the vOX2:Fc mass). Therefore, the dimer-monomer dissociation model was applied to fit the data. The experimental SE curves and data fit are shown in (Fig. 5B and C) . As a best-fit result of this data treatment, the averaged molecular mass for vOX2 monomer was 33.572 kDa obtained with v of 0.695 ml/mg (at 4 1C) and the dimer-monomer dissociation constant was 16 μM. The dissociation constant value was assessed by applying it to the results of the SV experiment. We have estimated the amount of monomer and dimer in vOX2 samples of different concentrations used in SV experiment: the equilibrium in the system was displaced towards monomeric species, what was reflected on c(s) distribution where the major peak was a monomer (Fig. 5A) . 
Discussion and conclusions
Since due to very strong adhesive activities, our attempts failed to reach a reliable structure of vOX2 using X-ray crystallography, the structural properties of the molecule were determined by biochemical, bioinformatics and biophysics. The vOX2:Fc protein was produced by engineered CHO cells as a recombinant Fc-fusion protein. The extracellular region of KSHV vOX2 fused to the CH2, CH3 domains and hinge region of Fc fragment of human IgG 1 (Fig. 2B) . The construction of fusion proteins enables the generation of recombinant proteins for structural, functional and therapeutic studies.
The extracellular region of KSHV vOX2 (aa 1-230) is glycosylated, since the protein contains at least five potential N-glycosylation sites, which confer an electrophoretic mobility of around 50 kDa (Fig. 3A , lanes 2, and C lane 2). Consistent with this post-translational modification, the 228 amino acids extracellular region of the protein predicted has a molecular weight of 24.6 kDa, calculated by bioinformatics servers from the known amino acid sequence. This finding also strongly suggested that vOX2 is highly glycosylated. Apparently, according to this study and other researchers, the full protein molecular weight containing intracellular region is approximately 55 kDa (Chung et al., 2002) . Deglycosylation of extracellular regions of protein showed that molecular weight reduced from 50 to 25 kDa (Fig. 4B, lanes 2-4) . Therefore, the molecular weight of oligosaccharide chains seems to be around 25 kDa or 100% increase in protein weight which is not rational for a glycoprotein. However, in the present study, considering bioinformatical model and predicted glycosylation sites along with biophysical analysis revealed that the glycosylated vOX2 should have a molecular mass of 32.0-33.6 kDa, corresponding to 30-36% glycosylation. This number is comparable to other glycosylated proteins participating in the immunological response such as CD80 family (Fairman et al., 1999) .
In our suggested model, high ERRAT score (96.3%) besides fine matching of bioinformatical and biophysical data, could provide more confidence on accuracy of bioinformatically determined three-dimensional model and infers that PD-L1 selection as a template is satisfactory. In addition, both vOX2 and PD-L1 structures are mainly composed of beta sheets and belong to Ig superfamily. Their biological functions are similar; like vOX2, PD-L1 engagement is followed by negative regulation of immune system (Freeman et al., 2000; Carter et al., 2002; Liechtenstein et al., 2012) .
The extracellular region of the vOX2 most likely represents the biologically important region of vOX2 through binding to the CD200-R1 (Foster-Cuevas et al., 2004) . The cytoplasmic region of the vOX2 lacks sequence identity with known signalling motifs, or typical docking sites for adaptor molecules (NCBI. BLAST and MotifScan programmes).
Initial analyses of vOX2 suggested that the N-terminal region of the molecule has 45% similarity with IgV-like domain and protein has an integrin-binding motif, RGD, at residues 191-193, C-terminal (Fig. 1C-3 and Fig. 2B ). The protein has no other sequence identity with other known protein motifs (NCBI. BLAST).
The PSI-BLAST analysis of vOX2 (in NCBI) also showed structural similarities with number of cell adhesion glycoproteins such as Nectin-1, Down Syndrome Cell Adhesion Molecule (Dscam) and NCAM. Because of structural similarity between vOX2 and proteins involved in cell adhesion, it used to refer to vNCAM or v-adh, which indicated its probable roll in cell to cell adhesion. In addition to structural similarity, the KSHV vOX2 protein has an RGD tri-peptide motif. In some proteins for instance, vitronectin, fibrinogen and Latency Associated Peptide (LAP) complex of TGF-β (Barczyk et al., 2010) , this motif participates in receptor interactions by binding to integrins. For example, the major integrin-binding site of NCAM lies on a segment of domain Ig6 that includes a RGD motif, which is recognised by integrins such as α v , two β1 integrins (α5 and α8) and αIIbβ3 (Chen and Chen, 2011; Sutherland et al., 2012) . Initially, KSHV vOX2 was speculated to be an adhesion molecule (vadh) (Russo et al., 1996) and a suggested homologue of NCAM. The existence of an RGD motif in vOX2 raises the possibility that the viral protein participates in cell adhesion. However, no such motif is present in CD200. This possibility was confirmed by dendritic cells (DCs) aggregation induced by vOX2 treatment (Chung et al., 2002) and our finding showed the same effect, vOX2-transfected Jurkat cells form large aggregate (data not shown). Moreover, as a homologue of CD200, it may participate in cell-cell contact in the site of the immunological synapse, particularly the monocyte/macrophage-tissue and APC-T cell synapses (Rezaee et al., 2006 ).
In the present study, our bioinformatics modelling results demonstrated that the RGD motif is exposed on the C-terminal domain of the protein surface. Furthermore, our data showed that vOX2 could form "side-to-side" dimers which could propound a possibility: homophilic binding between two adjacent cells by dimerising vOX2 molecules present on cell surface, like NCAMs (Rao et al., 1993; Sandig et al., 1994) . The homophilic interaction between NCAMs on adjacent cells appears in some instances and requires the presence of heparan sulphate as a co-receptor (Cole et al., 1986) . In addition to homophilic binding, vOX2 participates in heterophilic binding, in which vOX2 binds to a counter-receptor, CD200Rs, present on the cells of immune system. However, further studies are required to determine whether this motif and "side-toside" dimerisation in vOX2 participate in cell contact.
vOX2 shares identity with the CD200 (Foster-Cuevas et al., 2004) . The role of cellular CD200 is modulation of the activities of myeloid lineage cells, perhaps via costimulatory signal alteration. Cellular CD200 protein belongs to a group of leucocyte Ig super-family glycoproteins including NCAM and Thy-1, which is generally expressed in both lymphoid and neuronal tissues (Clark et al., 1985) . CD200 contributes to various activities that NCAM also influences, for example, morphogenesis, neural development (Morris and Beech, 1987) , neuronal cell to figure, of the six residues, five were identified in the extracellular region of vOX2 (N1-N5), and only one in the Fc fragment of the recombinant protein (N6). (B): The vOX2 fusion protein was treated with increasing amounts of PNGase F. After treatment, the protein was analysed by SDS-PAGE under reducing and denaturing conditions and stained with Coomassie Blue to reveal the diffuse band of vOX2 that originally migrated as a molecular mass of 50 kDa shifted to a molecular mass of 25 kDa consistent with that of the predicted molecular mass of the protein lacking glycosylation. Lane 1, denatured vOX2 þ water; Lane 2, denatured vOX2 þ 0.25 units PNGase; Lane 3, denatured vOX2 þ2.5 units PNGase, and Lane 4, denatured vOX2 þ5 units PNGase. The molecular size markers (kDa) are shown at the left of the gel and the blots.
cell interaction and growth of dendrites and axons (Bartolome et al., 2002) . Thus, CD200 and NCAM could act as complementary glycoproteins during the development and organisation of the nervous system. Moreover, CD200 has been identified as an immunoregulatory molecule in immune privileged organs such as the CNS (Koning et al., 2009) and eye (Broderick et al., 2002) . The immune status of the CNS and eye is strictly regulated and responses are kept to a minimum. In contrast, the distribution of CD200 receptor family in human is more restricted to myeloid and T cells (Wright et al., 2003) than that of CD200, suggesting the CD200/CD200R interaction acts locally to modulate inflammatory-cell activity at sites of tissue damage. Overall, vOX2 in KSHV may also provide an immunological privilege site for the virus to escape from host immune responses.
Functional studies with the purified vOX2:Fc protein in vitro revealed that it specifically reduced the oxidative burst of primary human neutrophils and the production of IL-8 by rIFN-γ-treated myeloid cell line to basal levels (Rezaee et al., 2005) and also suppressed phosphorylation of ERK1/2 MAP kinase in T cells which was followed by reduced specific T cell responses (Karen . Therefore, besides Ig superfamily structure, it functionally belongs to the B7 family of accessory molecules such as CD80, CD86 and PD-L1. Among B7 family members, bioinformatics studies showed that structural and functional properties of PD-L1 made it a good candidate to be used as a template to model KSHV vOX2. Alongside with their structural similarity, biophysical and functional activities of these two proteins are comparable. Like vOX2/CD200R1 weak engagement, PD-L1 and PD-1 interaction is much weaker than expected which might result in weak PD-1/PD-L1 complex (Cheng et al., 2013) . Engagement of PD-L1 to its receptor, PD-1, negatively regulates T lymphocytes (Freeman et al., 2000; Carter et al., 2002; Liechtenstein et al., 2012) . PD-1 pathway could affect broad ranges of immune responses and exerts significant effects in clinical conditions such as autoimmunity, viral infection and anti-tumor immunity . Blockade of PD-1/PD-L1 interaction might have therapeutic application and recently has been used in patients with advanced haematologic malignancies with remarkable results (Berger et al., 2008) . Like PD-L1, vOX2 can provide negative regulatory signals for modulating of immune responses, particularly monocyte/ macrophage (Foster-Cuevas et al., 2004) , CD8 þ T cell ) and neutrophil function (Rezaee et al., 2005) .
In conclusion, our analyses revealed that vOX2 exists in monomer-dimer equilibrium and is composed predominantly of betasheets with a putative integrin-binding RGD motif, exposed on the C-terminal of the molecule. The molecular weight of extracellular Fig. 5 . The results of sedimentation velocity (A) and sedimentation equilibriums (B and C) for both Fc-tagged and cleaved vOX2 samples. Sedimentation velocity (SV) and sedimentation equilibrium (SE) experiments were carried out on a Beckman Coulter (Palo Alto, CA, USA) Optima XL-I analytical ultracentrifuge using both absorbance at 280 nm and interference optics. The experimental temperature for all AUC runs was 4 1C. The sample volume was 100 and 400 μM for SE and SV, respectively; the sample concentrations were ranged between 0.09 and 1 mg/ml. (A) Comparative SV characterisation of vOX2:Fc and vOX2. Insets: the concentration dependence of the weightaverage sedimentation coefficient obtained by integration of c(s) distribution; the sedimentation coefficients calculated for glycosylated monomer (sphere) and glycosylated dimer (two spheres) are indicated by arrows; c(s) distribution of vOX2:Fc in solution is shown at 45,000 rpm (interference data), and c(s) distribution of vOX2 in solution is shown at 48,000 rpm (absorbance data). (B) Sedimentation equilibrium (SE) data obtained at 11,500 rpm and 15,000 rpm, c ¼ 0.35 mg/ml were fit to single species model; (C) SE data obtained at 25,000 rpm; the data were fit to monomer-dimer association model. domains of vOX2 is much less than expected 50 kDa, as observed in SDS PAGE, and is 32.0-33.6 kDa in which by considering 5 kDa transmembrane region and intracellular tail, molecular weight of complete protein will be 37.0-38.6 kDa. Taking together, the bioinformatics, biochemical and our previous results indicate that KSHV vOX2 due to similarity to PD-L1, high adhesive properties and implication of its cellular homolog (CD200) in neurogenesis, might be considered as an adhesive immunomodulatory protein of Ig superfamily molecules, particularly immune-inhibitory members of B7 family. However, due to the controversial functions of KSHV vOX2 and its cellular counterpart CD200, it needs more studies to validate the biological activities of these molecules.
Materials and methods
Bioinformatics
The amino acid sequence of vOX2 was analysed using PROSITE (http://prosite.expasy.org/) and NetNGlyc 1.0 tools (http://www. cbs.dtu.dk/services/NetNGlyc/) in order to reveal folding patterns peculiar to vOX2 amino acid sequence and identify N-glycosylation sites, respectively.
Water-soluble vOX2 has 231 amino acids broadly consisting of two domains: an N-terminal domain including IgV-like folding pattern recognised by PSI-BLAST (the residues 1-130) and C-terminal domain (the residues 131-231). Position-Specific Iterative Basic Local Alignment Search Tool (PSI-BLAST) derives a position-specific scoring matrix (PSSM) or profile from the multiple sequence alignment of sequences detected above a given score threshold using protein-protein BLAST (Bhagwat, 2007) . Threedimensional models of the vOX2 sequences were constructed by homology modelling. BLAST sequence homology searches were performed in order to identify the template proteins by PSI-BLAST (http://www.ncbi.nlm.nih.gov/BLAST/) (Altschul et al., 1997) ). Multiple alignments were carried out on the selected sequences by ClustalX2 (protein weight matrix: BLOSUM series). For this alignment analysis, the 24 amino acid signal peptide was removed. Protein modelling was performed by MODELLER9v9 (http://salilab. org/modeller/). In MODELLER, predicted structures were assigned a molecular probability density function (molpdf) score based on the sum of all restraints. By molpdf, models could be ranked from the same alignment; lower molpdf means the restraints are better satisfied and gains better score in model validation. Structure refinements and energy minimisation performed by a Hyper Chem7.5 (Hypercube Inc., http://www.hyper.com/) under a molecular mechanic AMBER method (RMS gradient¼0.5). All models were validated using the programme ERRAT (Colovos and Yeates, 1993 ) (UCLA, http://nihserver.mbi.ucla.edu/savs/). ERRAT has an "Overall quality factor" ranging from 0 to 100. Acceptable scores depend on protein size and models with better quality (less error prone regions) gaining higher scores.
Construction of expression vectors
Sequences encoding the extracellular region of KSHV vOX2 gene (V8) (Fig. 2A) were PCR amplified. The gene was cloned from the BC-1 KSHV-infected PEL cell line (Cesarman et al., 1995) into the pCR2.1 TA cloning vector, where the sequence was verified, then subcloned into an expression vector. The gene was amplified using Platinum Pfx (Invitrogen, Paisley, Scotland) with the relevant primers as follows: sense, 5 0 -GCT CTA GAT GTC TAG CCT CTT CAT TTC ATT AC-3 0 ; antisense, 5 0 -TAT GCG GCC GCG GCC GCG GGA AGG TCA TGG GC-3 0 . These amplification primers included restriction sites (Xba I and Not I) enabling subcloning of the gene into the expression vector. Sequencing of both strands of the V8 gene in both directions confirmed that no errors had been introduced by PCR. After sequencing, V8 gene was subcloned into the pDR2Δ EF1α.Fc expression vector (see (Charreau et al., 1994; Spiller et al., 2003) to create pDR2ΔEF1α.V8:Fc expression vectors in which the vOX2 gene was cloned upstream and in frame of the Fc fragment of IgG 1 . Subcloning involved digestion of the V8 insert from pCR2.1-TOPO constructs with Xba I and Not I and ligation into Spe I and Not I digested pDR2ΔEF1α.Fc. Expression plasmid was then sequenced over the sites at which the V8 DNA fragments were cloned to ensure that the ligation had generated an in-frame fusion of the viral and IgG 1 Fc genes.
Cell transfection
Chinese hamster ovary cells (CHO) were transfected with a Lipofectamine (Invitrogen, Paisley, Scotland) method. Transfection was carried out by incubating the cells at 50% confluency (7 Â 10 5 cells) overnight prior to transfection in 60 mm dishes. On the day of transfection, the purified DNA (25 ng in 100 μl serum free medium) was mixed with Lipofectamine mixture (5 μl Lipofectamine with 95 μl serum free medium) and incubated at room . Far UV (A ) and near UV (B) circular dichroism spectra for cleaved vOX2 at 0.2 mg/ml in phosphate buffer (91.5 mM Na 2 HPO 4 , 58.5 mM NaH 2 PO 4 , pH 7.4). The data were best fitted with 3% alpha-helix, 38% beta-sheet, 24% beta-turn and 35% other.
temperature for 45 mins. Then 0.8 ml serum free medium was added to the DNA-lipofectamine mixture and plated onto the cells and incubated at 37 1C for 5 h. Medium containing DNA was then removed and, 1 ml antibiotic free, 20% serum medium was added. After transfection (72 h post addition of DNA), the medium was replaced with selective medium containing 400 μg ml À 1 Hygromycin B. This minimal concentration of Hygromycin B required to kill untransfected cells, was determined by performing a dose response analysis. Following selection, cells transfected with pDR2EF1α were maintained with Hygromycin B (100 μg ml
).
Protein purification
vOX2:Fc transfected CHO cells cultured in RPMI-1640 were supplemented with 4% FCS, Glutamine (2 mM), Ampicillin/streptomycin (100 IU/ml and 100μg/ml, respectively) and non-essential amino acids (100 μM). Cell culture supernatants were stored at 4 1C until the volume exceeded 2 l. In the current study an automated two-step purification method (AKTA protein purifier system, Amersham) for the Fc fusion protein was chosen based on capture by affinity chromatography, followed by "polishing" with gel filtration. Affinity chromatography on HiTrap recombinant protein A was chosen for its high selectivity for IgG 1 . Suitable conditions for binding and elution buffers were optimised, in which a two-step elution system was selected. In the first step, to remove low affinity molecules such as bovine Ig, a 0.1 M sodium citrate buffer (pH 5.0) was used, and in the next step a 0.1 M glycine/HCl buffer (pH 3.0) elution buffer was selected. Immediately to neutralise the low pH and prevent protein degradation, Tris buffer (pH 9.0) was added to collected proteins. To remove low or trace levels of contaminants, such as aggregates and degraded fragments including truncated vOX2:Fc and Fc protein fragments, the proteins were 'polished' by gel filtration on a HiLoad 16/60 Superdex 200 size exclusion column.
Protein purity
All purified protein fractions were examined by SDS-PAGE gel and Western Blot detection with anti-human IgG-HRP. Identity was confirmed by MALDI-TOF and tandem MS (from protein A purified protein). The concentration of cleaved vOX2 and vOX2:Fc was determined by absorbance spectroscopy at 280 nm using an extinction coefficient (ε) of 2.05 cm 2 mg À 1 and 1.65 cm 2 mg À 1 respectively; these values were calculated from the amino acid sequences of the proteins. The protein concentration was also assayed by Bradford assay (Bradford, 1976) .
Fc-tag removal
The Fc component of human IgG 1 was removed from recombinant vOX2:Fc with Factor Xa enzyme (Novagen). A linker region placed between the vOX2 fragment and the Fc tag of the vOX2:Fc fusion sequence contains a factor Xa cleavage site. vOX2:Fc fusion protein was cleaved using an Xarrest™ Agarose kit (Novagen) according to the manufacturer's instruction. After cleavage, Factor Xa was removed from the reaction by affinity capture on. To purify cleaved vOX2 and Fc, the post-Xarrest solution (protease-free) is then loaded onto the protein A column and washed with the equilibration/loading buffer. The protein fractions were checked by SDS-PAGE under reducing conditions with Coomassie Blue staining and Western Blot, using anti-vOX2 monoclonal antibodies and anti-human IgG-HRP. The identity of bands in the Coomassie Blue stained gel was then confirmed with tryptic mass spectrometry (MALDI-TOFF).
vOX2 protein deglycosylation
Deglycosylation was carried out using a PNGase F kit (NEB, UK), according to manufacturer's instruction, briefly. The purified vOX2 fragment of the vOX2:Fc fusion protein was introduced to 0.25, 2.5 and 5 units of PNGase F under denaturing condition. 10 mg of protein was combined with denaturing buffer and distilled water to make a 10 μl total reaction volume, heated at 100 1C for 10 min. Then PNGase F with other additives incubated for 60 min at 37 1C. After the treatment, normal and deglycosylated proteins were introduced to Coomassie Blue staining of SDS-PAGE under reducing and denaturing conditions.
Circular dichroism spectroscopy
Circular dichroism (CD) spectra of cleaved vOX2 were recorded at 20 1C using a JASCO J-600 spectropolarimeter (JASCO UK Ltd., UK). The far ultra violet (UV) CD spectrum (260-190 nm) of vOX2 was measured using a 0.02 cm path length quartz cell at the speed of 50 nm/min and response 0.5 s, 8 scans were taken. The near UV CD spectrum (320-260 nm) of vOX2 was obtained in 0.2 cm path length quartz cell at the speed of 20 nm/min and response 1 s, 4 scans were taken. The protein concentration was 0.2 mg/ml in phosphate buffer (91.5 mM Na 2 HPO 4 , 58.5 mM NaH 2 PO 4 , pH 7.4). Secondary structure estimations were obtained using the Provencher and Glockner method (Provencher and Glockner, 1981) .
Analytical ultracentrifugation (AUC)
Sedimentation velocity (SV) and sedimentation equilibrium (SE) experiments were carried out on a Beckman Coulter (Palo Alto, CA, USA) Optima XL-I analytical ultracentrifuge using both absorbance at 280 nm and interference optics. The experimental temperature for all AUC runs was 4 1C. The sample volume was 100 μl and 400 μM for SE and SV respectively, and the sample concentrations were ranged between 0.09 and 1 mg/ml. SV experiments were carried out at rotation speed of 45,000 and 48,000 rpm for vOX2:Fc construct and cleaved vOX2 respectively. Partial specific volumes (v) for the protein part of vOX2 itself and vOX2:Fc were calculated from the protein amino acid sequence, using the programme SEDNTERP (Laue et al., 1992) and extrapolated to the experimental temperature following the method of Durchschlag (Durchschlag, 1986) . The contribution of carbohydrate part in molecular weight of Fc-tag was estimated using following formula (Durchschlag, 1986) . Both density and viscosity of PBS buffer at the experimental temperature were calculated using SEDNTERP. Sedimentation velocity profiles were treated using size-distribution c(s) model implemented in the programme SEDFIT (Schuck, 2000) . In order to determine the mass of each species, the c(s) distribution was converted to c(M) distribution. Each peak on the distribution plot was integrated in order to obtain the weight-averaged values for sedimentation coefficient and molecular mass. Integrated values of sedimentation coefficient (s) obtained at experimental conditions were converted to the standard conditions (s 20,w ) (which is the value of sedimentation coefficient in water at 20 1C).
Equilibrium in SE experiments was attained after 45 h. SE traces for vOX2:Fc were obtained at 11,500 15,000 and 25,000 rpm. True optical baselines were obtained after a further 6 h of rotation at 48,000 rpm. SE data were fitted globally using both the Beckman XL-A-XL-I software implemented in Microcal ORIGIN 6.0 and the NONLIN programme (Johnson et al., 1981) (WINDOWS version). The "fringe extinction coefficient" N derived from SV data was used to convert the association constant in inverse fringe units to a dissociation constant in molar units. The molecular weight of glycosylated vOX2:Fc was estimated using following formula (Lewis and Junghans, 2000) M ¼ M 
